Related Experiment Videos
99mTc-labelled compounds prepared with molybdenum III as reducing agent
The International Journal of Applied Radiation and Isotopes
|March 1, 1984
Summary
Molybdenum(III) successfully reduces pertechnetate for radiopharmaceutical labeling. Different technetium complexes show varied biodistribution, with [99mTc]Mo-HEDSPA accumulating in bones and [99mTc]gluconate complexes targeting kidneys or bones.
Area of Science:
- Radiochemistry
- Nuclear Medicine
- Pharmacology
Background:
- Pertechnetate (TcO4-) is a common radiotracer but requires labeling for specific organ targeting.
- Molybdenum(III) has been explored as a reducing agent for pertechnetate labeling.
- Understanding the biodistribution of technetium complexes is crucial for diagnostic imaging.
Purpose of the Study:
- To evaluate the efficacy of Molybdenum(III) in reducing pertechnetate for labeling with DTPA, HEDSPA, and gluconate.
- To investigate the biodistribution and organ accumulation of the resulting technetium complexes after intravenous administration.
- To characterize different technetium-gluconate complexes based on reduction time and their biological behavior.
Main Methods:
- Radiolabeling of DTPA, HEDSPA, and gluconate using Mo(III) to reduce Tc-99m pertechnetate at pH 5.5.
- Intravenous administration of radiolabeled complexes ([99mTc]Mo-DTPA, [99mTc]Mo-HEDSPA, [99mTc]gluconate) in biological experiments.
- Measurement of organ accumulation and biodistribution of Tc-99m activity over time.
Main Results:
- Mo(III) reduction of pertechnetate was successful for DTPA, HEDSPA, and gluconate labeling.
- [99mTc]Mo-DTPA was rapidly cleared from the body with no significant organ accumulation.
- [99mTc]Mo-HEDSPA showed significant accumulation in bones (42% within 1 hour).
- Two types of technetium-gluconate complexes were formed: Complex I (1-3 min reduction) accumulated in kidneys (20% within 2 hours), while Complex II (45 min reduction) accumulated in bones (12% within 2 hours).
Conclusions:
- Molybdenum(III) is a viable reducing agent for Tc-99m radiolabeling.
- The choice of chelator and reduction time significantly influences the biodistribution of Tc-99m complexes.
- [99mTc]Mo-HEDSPA and Tc-99m-gluconate Complex II are bone-seeking agents, while Tc-99m-gluconate Complex I shows renal affinity.